Centaurus Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

Centaurus Financial’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5	Closed	–	–	2388
2018 Q2	$0	Buy	+5	New	+$35	﹤0.01%	2485

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Centaurus Financial's INSY Position: Q3 2018 in Review

Centaurus Financial sold out of Insys Therapeutics, Inc. (INSY) in Q3 2018, closing a stake of 5 shares.

Centaurus Financial first reported a position in INSY in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 110 funds tracked by Wall St. Rank hold INSY as of Q3 2018.

Centaurus Financial reported no remaining Insys Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 5 Insys Therapeutics, Inc. shares in Q3 2018.
Centaurus Financial first reported a position in Insys Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Insys Therapeutics, Inc. position peaked at $0 in Q2 2018.
110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.